Your browser doesn't support javascript.
loading
Structure of the cell-binding component of the Clostridium difficile binary toxin reveals a di-heptamer macromolecular assembly.
Xu, Xingjian; Godoy-Ruiz, Raquel; Adipietro, Kaylin A; Peralta, Christopher; Ben-Hail, Danya; Varney, Kristen M; Cook, Mary E; Roth, Braden M; Wilder, Paul T; Cleveland, Thomas; Grishaev, Alexander; Neu, Heather M; Michel, Sarah L J; Yu, Wenbo; Beckett, Dorothy; Rustandi, Richard R; Lancaster, Catherine; Loughney, John W; Kristopeit, Adam; Christanti, Sianny; Olson, Jessica W; MacKerell, Alexander D; Georges, Amedee des; Pozharski, Edwin; Weber, David J.
Afiliación
  • Xu X; City University of New York Advanced Science Research Center, City University of New York, New York, NY 10017.
  • Godoy-Ruiz R; PhD Program in Biochemistry, The Graduate Center, City University of New York, New York, NY 10017.
  • Adipietro KA; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Peralta C; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850.
  • Ben-Hail D; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Varney KM; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Cook ME; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Roth BM; City University of New York Advanced Science Research Center, City University of New York, New York, NY 10017.
  • Wilder PT; City University of New York Advanced Science Research Center, City University of New York, New York, NY 10017.
  • Cleveland T; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Grishaev A; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850.
  • Neu HM; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Michel SLJ; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Yu W; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Beckett D; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Rustandi RR; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Lancaster C; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850.
  • Loughney JW; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Kristopeit A; National Institute of Standards, Rockville, MD 20899.
  • Christanti S; National Institute of Standards, Rockville, MD 20899.
  • Olson JW; University of Maryland School of Pharmacy, University of Maryland, Baltimore, MD 21201.
  • MacKerell AD; University of Maryland School of Pharmacy, University of Maryland, Baltimore, MD 21201.
  • Georges AD; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850.
  • Pozharski E; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Weber DJ; University of Maryland School of Pharmacy, University of Maryland, Baltimore, MD 21201.
Proc Natl Acad Sci U S A ; 117(2): 1049-1058, 2020 01 14.
Article en En | MEDLINE | ID: mdl-31896582
ABSTRACT
Targeting Clostridium difficile infection is challenging because treatment options are limited, and high recurrence rates are common. One reason for this is that hypervirulent C. difficile strains often have a binary toxin termed the C. difficile toxin, in addition to the enterotoxins TsdA and TsdB. The C. difficile toxin has an enzymatic component, termed CDTa, and a pore-forming or delivery subunit termed CDTb. CDTb was characterized here using a combination of single-particle cryoelectron microscopy, X-ray crystallography, NMR, and other biophysical methods. In the absence of CDTa, 2 di-heptamer structures for activated CDTb (1.0 MDa) were solved at atomic resolution, including a symmetric (SymCDTb; 3.14 Å) and an asymmetric form (AsymCDTb; 2.84 Å). Roles played by 2 receptor-binding domains of activated CDTb were of particular interest since the receptor-binding domain 1 lacks sequence homology to any other known toxin, and the receptor-binding domain 2 is completely absent in other well-studied heptameric toxins (i.e., anthrax). For AsymCDTb, a Ca2+ binding site was discovered in the first receptor-binding domain that is important for its stability, and the second receptor-binding domain was found to be critical for host cell toxicity and the di-heptamer fold for both forms of activated CDTb. Together, these studies represent a starting point for developing structure-based drug-design strategies to target the most severe strains of C. difficile.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas Bacterianas / Toxinas Bacterianas / Clostridioides difficile / ADP Ribosa Transferasas / Enterotoxinas Límite: Animals Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas Bacterianas / Toxinas Bacterianas / Clostridioides difficile / ADP Ribosa Transferasas / Enterotoxinas Límite: Animals Idioma: En Año: 2020 Tipo del documento: Article